search
Back to results

Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum

Primary Purpose

Obesity, Wound Infection, Pregnancy

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Kerlix-AMD
placebo--normal gauze
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Obesity

Eligibility Criteria

15 Years - 50 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • pregnant women at LHSC with BMI >40

Exclusion Criteria:

  • pregnant women who cannot understand English, who have a fetal demise or who have a pre-existent infected skin infection at the site of c-section

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Placebo Comparator

    Experimental

    Placebo Comparator

    Arm Label

    Elective LSCS--Kerlix AMD

    Elective LSCS--Placebo

    Labouring LSCS--Kerlix AMD

    Labouring LSCS--Placebo

    Arm Description

    Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks

    Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks

    Kerlix-AMD applied to wound post-operatively for 2 weeks

    Normal gauze applied to wound post-operatively for 2 weeks

    Outcomes

    Primary Outcome Measures

    surgical site infection
    All patients will have their wounds assessed by 6 weeks post partum to evaluate for the presence (or absence) of surgical site infection, using the Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria.

    Secondary Outcome Measures

    patient satisfaction
    patients will be surveyed on adherence and acceptability of application of gauze post c-section

    Full Information

    First Posted
    May 12, 2016
    Last Updated
    August 24, 2016
    Sponsor
    Lawson Health Research Institute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02882360
    Brief Title
    Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
    Official Title
    The Use of Antimicrobial Gauze in Pregnant Women Undergoing C-section With BMI >40 to Decrease Wound Complications by 6 Weeks postpartum--a Small Feasibility Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2016 (undefined)
    Primary Completion Date
    January 2018 (Anticipated)
    Study Completion Date
    December 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Lawson Health Research Institute

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Pregnant women with BMI>40 will be approached for participation in a study to reduce the rate of post-operative wound infection from C-section. Women will be randomized to a commonly used wound product (Kerlix-AMD) which consists of a PHMB-impregnated gauze versus normal gauze, and rates of post-operative surgical site infection will be assessed. Women with a planned procedure will also be randomized to applying Kerlix versus gauze for 3 days pre-operatively to determine if this improves outcomes as well.
    Detailed Description
    This study be a randomized double-blinded feasibility study to improve the rates of wound complications post-C/S in women with a BMI >40. It will be conducted out of a single tertiary care centre in London, Ontario. The women will be randomized to one of two treatment groups, either Kerlix AMD gauze or Kerlix plain gauze (Kendall, Covidien AG, Mansfield MA). This randomization will be performed by validated computer based randomization software (www.sealedenvelope.com). The patients, staff and physicians will be blinded to the assigned groups. After consenting to the study, at the time of their C/S, participants will be assigned a sealed envelope which will contain their assigned group. All patients with a BMI >40 who qualify for the study that are seen in the outpatient clinics at our centre will be approached about their participation in the study. Patients that meet the study criteria who are seen for the first time after being admitted to the labor and delivery ward will be consented for the study, and if they do not require a C/S, then this consent will be disregarded. Participants who have a planned C/S will also be randomized to receive treatment with either AMD or plain gauze for three days prior to their C/S. This requires placement of a piece of gauze, randomly assigned, under the pannus in the area of the anticipated incision. This gauze is to be changed daily for three days prior to the booked C/S. These patients will continue to receive the same gauze they were assigned to post-operatively. As part of routine care peri-operatively, all patients receive 3g of Ancef 15-60 min prior to skin incision (Ayres-de-Campos), and their skin is prepped with 2% chlorohexidine (Lee I) (2%, Laboratoire Atlas Inc, Montreal, QC) . The subcutaneous layer will be closed at the end of the case using absorbable sutures (Chelmow). The skin will be closed with a running absorbable suture in the subcuticular layer (Clay). At the end of the C/S, all patients will have their respective gauze placed over their incision, with a Tegaderm (3M Healthcare, St. Paul, MN) or pressure dressing placed on top. This outer occlusive dressing will be removed poat-operative day )POD) 1, unless it becomes saturated before then. Their gauze will be replaced daily, or more frequently if it becomes saturated. The incisions will be inspected daily by a physician while they are in hospital. The Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria will be used to diagnose wound infections. They will be discharged home with enough gauze for daily dressing changes for two weeks, as well as an information sheet outlining signs and symptoms to be aware of, or reasons to return to hospital. Their incision will be inspected by a physician at one, two and six weeks post-operatively. If at any point over the duration of the study they develop signs or symptoms of infection or any other complications, they will be investigated and treated accordingly. This may involve taking a picture of the wound to track whether or not cellulitis or infection is spreading or tracking; this will always be with your explicit consent and to track wound progression. At six weeks they will also complete a qualitative survey investigating their subjective experience with the gauze and the protocol. A cost analysis will also be performed. All data will be collected using data collection sheets. The newest version of Statistical Package for Social Sciences (SPSS) Statistical analysis software will be used to conduct data analysis, using formulas such as student t-test for continuous data and chi-squared for nominal data.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Obesity, Wound Infection, Pregnancy

    7. Study Design

    Primary Purpose
    Health Services Research
    Study Phase
    Phase 4
    Interventional Study Model
    Factorial Assignment
    Masking
    ParticipantCare ProviderOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Elective LSCS--Kerlix AMD
    Arm Type
    Experimental
    Arm Description
    Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
    Arm Title
    Elective LSCS--Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
    Arm Title
    Labouring LSCS--Kerlix AMD
    Arm Type
    Experimental
    Arm Description
    Kerlix-AMD applied to wound post-operatively for 2 weeks
    Arm Title
    Labouring LSCS--Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Normal gauze applied to wound post-operatively for 2 weeks
    Intervention Type
    Device
    Intervention Name(s)
    Kerlix-AMD
    Intervention Description
    Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
    Intervention Type
    Other
    Intervention Name(s)
    placebo--normal gauze
    Intervention Description
    Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
    Primary Outcome Measure Information:
    Title
    surgical site infection
    Description
    All patients will have their wounds assessed by 6 weeks post partum to evaluate for the presence (or absence) of surgical site infection, using the Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria.
    Time Frame
    6 weeks
    Secondary Outcome Measure Information:
    Title
    patient satisfaction
    Description
    patients will be surveyed on adherence and acceptability of application of gauze post c-section
    Time Frame
    6 weeks

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: pregnant women at LHSC with BMI >40 Exclusion Criteria: pregnant women who cannot understand English, who have a fetal demise or who have a pre-existent infected skin infection at the site of c-section
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Debbie Penava, MD
    Phone
    5196466401
    Email
    Debbie.Penava@lhsc.on.ca
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jennifer Ryder, HBSc, MHS
    Phone
    519-685-8781
    Email
    Jennifer.Ryder@lhsc.on.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Debbie Penava, MD
    Organizational Affiliation
    Lawson Health Research Institute
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum

    We'll reach out to this number within 24 hrs